P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. (23rd June 2022) - Senapati, J.; Kantarjian, H.; Short, N.; Alvarado, Y.; Burger, J.; Jain, N.; Konopleva, M.; Ravandi, F.; DiNardo, C.; Masarova, L.; Sasaki, K.; Thompson, P. A.; et al.